Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
1(13%)
Results Posted
167%(5 trials)
Terminated
3(38%)

Phase Distribution

Ph not_applicable
1
13%
Ph phase_2
1
13%
Ph phase_3
2
25%
Ph phase_4
2
25%
Ph phase_1
1
13%
Ph early_phase_1
1
13%

Phase Distribution

2

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
1(12.5%)
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
2(25.0%)
Phase 4Post-market surveillance
2(25.0%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(3)
Terminated(4)

Detailed Status

Completed3
Terminated3
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (12.5%)
Phase 11 (12.5%)
Phase 21 (12.5%)
Phase 32 (25.0%)
Phase 42 (25.0%)
N/A1 (12.5%)

Trials by Status

completed338%
withdrawn113%
terminated338%
recruiting113%

Recent Activity

1 active trials
Showing 5 of 8
recruitingphase_1

Nicotinic Acid for the Treatment of Alzheimer's Disease

NCT06582706
withdrawnearly_phase_1

Early Aortic Valve Lipoprotein(a) Lowering Trial

NCT02109614
completedphase_4

Niacin, N-3 Fatty Acids and Insulin Resistance

NCT00286234
completedphase_2

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

NCT00359281
terminatedphase_3

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

NCT00108485
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06582706Phase 1

Nicotinic Acid for the Treatment of Alzheimer's Disease

Recruiting
NCT02109614Early Phase 1

Early Aortic Valve Lipoprotein(a) Lowering Trial

Withdrawn
NCT00286234Phase 4

Niacin, N-3 Fatty Acids and Insulin Resistance

Completed
NCT00359281Phase 2

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

Completed
NCT00108485Phase 3

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

Terminated
NCT00120289Phase 3

Niacin Plus Statin to Prevent Vascular Events

Terminated
NCT00986986Not Applicable

Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

Completed
NCT00397657Phase 4

Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8